NCT04687280

Brief Summary

The detection and diagnosis of hepatocellular carcinoma is a public health issue. MRI is the most sensitive examination for diagnosis and especially hypervascularization in the arterial phase. Several studies have shown that MRI multiphase arterial sequences are superior to single phase to capture the arterial phase. The purpose of this study is to compare arterial enhancement sensibilities between multi and single phase sequences.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
153

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2009

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 22, 2009

Completed
8.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 27, 2017

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

November 26, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 29, 2020

Completed
Last Updated

December 29, 2020

Status Verified

December 1, 2020

Enrollment Period

8.5 years

First QC Date

November 26, 2020

Last Update Submit

December 22, 2020

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

  • arterial enhancement

    significant arterial enhancement present in one of the three phases of multiphasic arterial time compared to all other arterial phases or single phase

    1 year

Interventions

non interventionalOTHER

non interventional, study on data

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patient followed up for cirrhosis with discovery of a suspicious CHC nodule during imaging monitoring

You may qualify if:

  • patient included in CHIC study with histology of hepatocellular carcinoma

You may not qualify if:

  • nodules already treated by chimioembolization

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 26, 2020

First Posted

December 29, 2020

Study Start

April 22, 2009

Primary Completion

October 27, 2017

Study Completion

December 1, 2018

Last Updated

December 29, 2020

Record last verified: 2020-12